Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence

British Journal of Cancer

Volumn 105, Issue 6, 2011, Pages 796-806

  Pandya, K ^a   Meeke, K ^b   Clementz, A G ^a   Rogowski, A ^a   Roberts, J ^b   Miele, L ^c   Albain, K S ^d   Osipo, C ^a,b,e  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e Department of Microbiology and Immunology ^*  (United States)

Author keywords

ErbB 2; GSI; Notch 1; recurrence; resistance; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA SECRETASE INHIBITOR; LAPATINIB; MRK 003; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NOTCH RECEPTOR; RNA; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENE ACTIVATION; GROWTH INHIBITION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR XENOGRAFT; WESTERN BLOTTING;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLIC S-OXIDES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE TARGETING; GENES, ERBB; GENES, ERBB-2; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, NOTCH; RECURRENCE; SIGNAL TRANSDUCTION; THIADIAZOLES;

EID: 80052494506     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.321     Document Type: Article

References (56)

1. Amar S, Moreno-Aspitia A, Perez EA (2008) Issues and controversies in the treatment of HER2 positive metastatic breast cancer. Breast Cancer Res Treat 109: 1-7 (Pubitemid 351538766)
2. Baselga J, Albanell J, Molina MA, Arribas J (2001) Mechanism of action of trastuzumab and scientific update. Semin Oncol 28: 4-11 (Pubitemid 33065104)
3. Baselga J, Bradbury I, Eidmann H, Di Cosimo S, Aura C, De Azabuja E, Gomez H, Dinh P, Fauria K, Van Dooren V, Paoletti P, Goldhirsch A, Chang T-W, Lang I, Unitch M, Gelber RD, Piccart-Gebhart M (2010) First results of the NeoALTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER-2 positive primary breast cancer. Cancer Res (Supplemental) 70: 1s-490s
4. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95 (Pubitemid 23063891)
5. Bettenhausen B, Hrabe de Angelis M, Simon D, Guenet JL, Gossler A (1995) Transient and restricted expression during mouse embryogenesis of Dll1, a murine gene closely related to Drosophila Delta. Development 121: 2407-2418
6. Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S (1997) Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 90: 281-291 (Pubitemid 27329713)
7. Brodie A, Macedo L, Sabnis G (2009) Aromatase resistance mechanisms in model systems in vivo. J Steroid Biochem Mol Biol 118: 283-287
8. Callahan R, Raafat A (2001) Notch signaling in mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia 6: 23-36 (Pubitemid 33640644)
9. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289
10. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648 (Pubitemid 29415219)
11. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE, Reedijk M (2007) High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 20: 685-693 (Pubitemid 46788875)
12. Dievart A, Beaulieu N, Jolicoeur P (1999) Involvement of Notch1 in the development of mouse mammary tumors. Oncogene 18: 5973-5981 (Pubitemid 29535009)
13. Dunwoodie SL, Henrique D, Harrison SM, Beddington RS (1997) Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. Development 124: 3065-3076 (Pubitemid 27387084)
14. Efferson CL, Winkelmann CT, Ware C, Sullivan T, Giampaoli S, Tammam J, Patel S, Mesiti G, Reilly JF, Gibson RE, Buser C, Yeatman T, Coppola D, Winter C, Clark EA, Draetta GF, Strack PR, Majumder PK (2010) Downregulation of notch pathway by a {gamma}-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res 70: 2476-2484
15. Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, Strack PR, Golde TE, Miele L, Foreman KE (2010) Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res 30: 3853-3867
16. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB (2010) Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 70: 709-718
17. Huober J, Loibl S, Darb-Esfahani S, Solbach C, Tesch H, Holms F, Fehm T, von Minckwitz G, Mehta K, Denkert C (2010) New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer-a translational investigation from the Neoadjuvant GeparQuattro Study. Cancer Res 70(24 Suppl): 100s
18. Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N, Johnston S (2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 10: 581-588
19. Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137: 216-233
20. Lacerda L, Pusztai L, Woodward WA (2010) The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches. Drug Resist Updat 13: 99-108
21. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672-679
22. Lindsell CE, Shawber CJ, Boulter J, Weinmaster G (1995) Jagged: a mammalian ligand that activates Notch1. Cell 80: 909-917
23. Logeat F, Bessia C, Brou C, LeBail O, Jarriault S, Seidah NG, Israel A (1998) The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proc Natl Acad Sci USA 95: 8108-8112 (Pubitemid 28326074)
24. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, Menard S, Tagliabue E (2009) Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin Cancer Res 15: 2010-2021
25. Menendez JA, Mehmi I, Lupu R (2006) Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemo-sensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 24: 3735-3746 (Pubitemid 46622312)
26. Mine T, Matsueda S, Li Y, Tokumitsu H, Gao H, Danes C, Wong KK, Wang X, Ferrone S, Ioannides CG (2009) Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother 58: 1185-1194
27. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC (1994) c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266
28. Nabholtz JM, Slamon D (2001) New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol 28: 1-12
29. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127 (Pubitemid 39485684)
30. Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123-138 (Pubitemid 43170962)
31. Nahta R, Yuan LX, Du Y, Esteva FJ (2007) Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 6: 667-674 (Pubitemid 46332467)
32. O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pitot HC, Chatterton R, Jordan VC (1998) Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 90: 1552-1558 (Pubitemid 28535720)
33. Orr B, Grace OC, Vanpoucke G, Ashley GR, Thomson AA (2009) A role for notch signaling in stromal survival and differentiation during prostate development. Endocrinology 150: 463-472
34. Osipo C, Gajdos C, Cheng D, Jordan VC (2005a) Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol 93: 249-256 (Pubitemid 40602497)
35. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC (2003) Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 95: 1597-1608 (Pubitemid 37455927)
36. Osipo C, Meeke K, Liu H, Cheng D, Lim S, Weichel A, Jordan VC (2005b) Trastuzumab therapy for tamoxifen-stimulated endometrial cancer. Cancer Res 65: 8504-8513 (Pubitemid 41330619)
37. Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L (2008) ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 27: 5019-5032
38. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L (2010) Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141-3152
39. Piechocki MP, Yoo GH, Dibbley SK, Lonardo F (2007) Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Cancer Res 67: 6825-6843 (Pubitemid 47105530)
40. Politi K, Feirt N, Kitajewski J (2004) Notch in mammary gland development and breast cancer. Semin Cancer Biol 14: 341-347 (Pubitemid 38993635)
41. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530-8537 (Pubitemid 41330622)
42. Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz RD, Osborne CK, Schiff R (2011) Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER-2/neu overexpressing breast tumor xenografts. Clin Cancer Res 17: 1351-1361
43. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96: 926-935 (Pubitemid 38868139)
44. Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, Deblandre GA, Kintner CR, Stark KL (2000) Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev 14: 1313-1318 (Pubitemid 30397075)
45. Slamon D, Pegram M (2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 28: 13-19
46. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712 (Pubitemid 19147683)
47. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA (1999) Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26: 60-70 (Pubitemid 29411434)
48. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726 (Pubitemid 34111379)
49. Widakowich C, Dinh P, de Azambuja E, Awada A, Piccart-Gebhart M (2008) HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? Anticancer Agents Med Chem 8: 488-496
50. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D, Venook R, Wu X, Ridgway J, Schahin-Reed D, Dow GJ, Shelton A, Stawicki S, Watts RJ, Zhang J, Choy R, Howard P, Kadyk L, Yan M, Zha J, Callahan CA, Hymowitz SG, Siebel CW (2010) Therapeutic antibody targeting of individual Notch receptors. Nature 464: 1052-1057
51. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 103: 7795-7800
52. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K, Plowman GD (2010) Chronic DLL4 blockade induces vascular neoplasms. Nature 463: E6-E7
53. Yao K, Rizzo P, Rajan P, Albain K, Rychlik K, Sha S, Miele L (2010) Notch-1 and Notch-4 receptors as prognostic markers in breast cancer. Int J Surg Pathol; e-pub ahead of print 5 May 2010; doi:10.1177/1066896910362080
54. Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2): 1-13 (Pubitemid 33033419)
55. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137 (Pubitemid 33674041)
56. Yokoyama G, Fujii T, Ogo E, Yanaga H, Toh U, Yamaguchi M, Mishima M, Takamori S, Shirouzu K, Yamana H (2005) Advanced chemoresistant breast cancer responding to multidisciplinary treatment with hyperthermia, radiotherapy, and intraarterial infusion. Int J Clin Oncol 10: 139-143 (Pubitemid 40655492)